Daiichi Sankyo's Once-Daily Anticoagulant Lixiana (Edoxaban) Receives Final Approval from the European EMA
Significance of Entering the European Market and Regulatory Approval
Daiichi Sankyo's oral Factor Xa inhibitor, Lixiana (Edoxaban), has received final approval from the European Medicines Agency (EMA), marking its official entry into the European market. This EMA approval, formalized on June 19, 2015, covers the prevention of stroke in patients with non-valvular atrial fibrillation and the treatment and prevention of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). This new drug, which significantly improves convenience and safety compared to the existing standard treatment, Warfarin, has been launched in over 30 European countries, providing patients with a new treatment option.
Proven Efficacy and Safety Through Large-Scale Phase 3 Clinical Trials
The scientific basis for this approval lies in the results of two large-scale Phase 3 clinical trials, ENGAGE AF-TIMI 48 and Hokusai-VTE, involving approximately 30,000 patients. In the ENGAGE AF-TIMI 48 study, which included 21,105 patients, Lixiana 60mg (once daily) demonstrated non-inferiority to Warfarin in preventing stroke and systemic embolism, while simultaneously exhibiting a superior safety profile with a 20% reduction in the risk of major bleeding (HR 0.80, 95% CI 0.71-0.91, p<0.001). Furthermore, the Hokusai-VTE trial, involving 8,292 patients, also achieved non-inferiority in preventing recurrent VTE (HR 0.89, 95% CI 0.70-1.13, p<0.001), with a rate of major and clinically meaningful non-major bleeding (CRNM Bleeding) of 8.5% compared to 10.3% in the control group, demonstrating superiority (HR 0.81, p=0.004).
Changes in the Global Anticoagulant Market and Competitive Landscape
The approval of Lixiana signals a shift in the global direct oral anticoagulant (DOAC) market, which has been dominated by Bayer's Xarelto (Rivaroxaban) and BMS/Pfizer's Eliquis (Apixaban). The global DOAC market is a highly attractive bio-sector, with a size exceeding $20 billion (USD) and continuing to grow to over $40 billion. Lixiana aims to expand its market share by leveraging its once-daily dosing convenience and superior safety profile in Asian patients compared to competing drugs. In particular, providing precise dose adjustment guidelines based on renal function (Creatinine Clearance) is expected to enhance prescription confidence in clinical practice and serve as a key strategy for market penetration.
Securing Daiichi Sankyo's Mid- to Long-Term Growth Engine
Lixiana is poised to become a key component of Daiichi Sankyo's next-generation pipeline and a major driver of the company's global revenue growth in the mid- to long-term. Having already overcome regulatory hurdles in Japan and the United States (brand name Savaysa), and now expanding into the European market, Daiichi Sankyo is further strengthening its position as a global multinational pharmaceutical company. It is expected to not only fill the revenue gap created by the impending patent expiration of existing flagship products but also grow into a blockbuster drug with annual sales of billions of dollars, significantly contributing to the company's financial stability.
Daiichi Sankyo's 'Lixiana' European approval marks the beginning of a full-fledged three-way competition in the global DOAC market, which is worth over $20 billion, against Eliquis (BMS/Pfizer) and Xarelto (Bayer). From an investor's perspective, it will fill the revenue gap caused by the patent expiration of existing flagship products and add a blockbuster drug with annual global sales of billions of dollars, strengthening Daiichi Sankyo's mid- to long-term cash flow. From a clinical researcher's perspective, the data from the ENGAGE AF-TIMI 48 and Hokusai-VTE Phase 3 trials, which demonstrated superior safety (20% reduction in the risk of major bleeding, HR 0.80) compared to Warfarin, is analyzed as a case that has raised the clinical safety standards for Factor Xa inhibitors to the next level. From the perspective of industry professionals, it will be an important regulatory milestone that allows them to understand the impact of precise dose adjustment guidelines based on renal function on new drug approvals and prescription guidelines. In the short term, it is expected to expand prescription volume through entry into the European market of over 30 countries, and in the mid- to long-term, it is expected to strengthen Daiichi Sankyo's position in the global cardiovascular treatment market.
Source: EMA (ema)